Navigation Links
Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
Date:10/26/2008

Iclaprim also achieved high eradication rates for the most common pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)

REINACH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated with a safety profile that compared favorably to linezolid. A New Drug Application for intravenous iclaprim in cSSSI will be discussed at the meeting of the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee on 20 November 2008.

Iclaprim, a novel antibiotic from the trusted dihydrofolate reductase (DHFR) selective inhibitor class of antibiotics, was specifically designed to address the growing need for additional treatment options to combat resistant infections including MRSA. MRSA affects more than 2 million people in the United States each year and rates of hospital- and community-acquired MRSA are on the rise.(i,ii)

"The high efficacy rates and favorable tolerability profile of iclaprim strongly supports its potential as a new treatment option for patients who have acquired serious infections caused by MRSA," said Dennis L. Stevens, MD, PhD, Veterans Affairs Medical Center, Boise, Idaho. "With rates of MRSA increasing and effectiveness of some current antibiotics declining, it is important to identify effective alternative treatments for these infections."

The results presented at the ICAA
'/>"/>

SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
(Date:1/23/2015)... South Africa , Jan. 23, 2015   Leatt ... of personal protective equipment for all forms of sports, ... flagship Leatt-Brace® neck brace, announced today that the UISP ... federation, now requires all riders to wear a neck ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... NEW YORK, Sept. 28, 2011 Visionsense Corp announces ... was used in its 500th neurosurgical procedure with the ... (Al Lerner Chair and Vice-Chairman, Dept of Neurosurgery at ... performed a transsphenoidal resection of a pituitary adenoma in ...
... 2011 Low rates of meningococcal vaccination among adolescents ... Human Services Agency (HHSA) to join forces with the ... San Diego Meningitis Awareness Week. A national public health ... third of adolescents in California have not been vaccinated ...
Cached Medicine Technology:Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 2Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 3Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 4Local School Nurses Unite Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens in San Diego 5
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... That can lead to under-reporting when applying for driver,s ... -- In patients with focal epilepsy, simply asking how ... of their seizure frequency, German research suggests. , Reminding ... not help, either, because they may be unaware of ...
... 15 Dr. Douglas Kalman of Miami Research,Associates delivered ... the,endurance athlete at the International Society of Sports Nutrition ... Kalman presented "Whey, Casein, Soy: Why Protein Sources are ... studies that examined just how, and if, these varied ...
... Mass., Nov. 15 Andy Ambrose has joined ... David Test, division sales manager. Ambrose is based ... relationships in,the south Texas region. He joins ... served as,regional vice president for the company,s retirement ...
... which don,t , THURSDAY, Nov. 15 (HealthDay News) -- Experts ... cystic fibrosis (CF). , The guidelines were based on a ... older. , "Physicians treating patients with CF are faced with ... clinicians will find these recommendations to be useful in their ...
... November 15, 2007 A recently published special ... the contributions from experts in the field of ... Fourth Annual Meeting on Brain aging and Dementia: ... Perugia in October 2006 under the auspices of ...
... to change diet, get more exercise, study found , THURSDAY, ... blood pressure are less likely than younger patients to receive ... their blood pressure, a new study finds. , A team ... data from a U.S. Centers for Disease Control and Prevention ...
Cached Medicine News:Health News:Some Epilepsy Patients Not Always Aware of Seizures 2Health News:Presentation at ISSN Highlights Soy Protein Advantages for Endurance Athletes 2Health News:Experts Release New Cystic Fibrosis Guidelines 2Health News:Journal of Alzheimer's Disease special issue explores multifaceted aspects of AD 2Health News:Journal of Alzheimer's Disease special issue explores multifaceted aspects of AD 3Health News:Older Hypertension Patients Less Likely to Get Lifestyle Advice 2
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
... Dehydroepiandrosterone (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is ... blood mostly in its,sulfate form ... is based on the competition ... An,unknown amount of DHEA-S present ...
Beta-2 Microglobulin EIA Lipid / Protein Quantification 025-BC-1061...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: